Fierce Pharma | October 22, 2026
UK regulator faults Otsuka over an event organizer's symposium webpage.
Fierce Pharma reports that the UK's Prescription Medicines Code of Practice Authority found Otsuka in breach of 11 clauses over the webpage for a symposium it sponsored at a 2025 healthcare congress. The page was publicly accessible, promoted the lupus nephritis drug Lupkynis outside its marketing authorization, and left out prescribing information. The regulator said Otsuka "appeared to have been let down" by the event organizers, because the problem text was missing from the drafts it checked, and it still held Otsuka responsible. A public page reaches patients as well as clinicians, and every reader takes it as the sponsor speaking. Pharma teams can add one step to congress planning: approve the live page after the organizer's final edit.